CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug ...

The US Food and Drug Administration (FDA) has approved updated mRNA vaccines from Moderna and Pfizer/BioNTech that protect ...

The approval letter to Pfizer and its BioNTech mentions the companies' commitment to conduct four postmarketing studies of ...

The Food and Drug Administration has approved updated COVID-19 vaccines for the upcoming fall and winter season.

Moderna’s updated COVID‑19 vaccines, Spikevax and the lower‑dose mNEXSPIKE, targeting the LP.8.1 variant, have been FDA‑approved for high‑risk groups and older adults. mNEXSPIKE offers improved ...

FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.

Moderna announced the Food and Drug Administration has approved the supplemental Biologics License Applications (sBLA) for the 2 025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 ...

Medical societies are increasingly issuing their own guidance in the face of a lack of or confusing recommendations from HHS.

US mRNA specialist Moderna yesterday announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for ...

The American Academy of Pediatrics called the decision to limit children's access to COVID-19 vaccines “deeply troubling.” ...

The FDA in May announced their plans to limit COVID vaccines to higher-risk groups, bypassing recommendations from the CDC's ...

As fall approaches, the Food and Drug Administration has authorized updated COVID-19 vaccines from both Pfizer-BioNTech and ...